KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Tax Provisions: 2017-2025

Historic Tax Provisions for Acadia Pharmaceuticals (ACAD) over the last 8 years, with Sep 2025 value amounting to -$27.2 million.

  • Acadia Pharmaceuticals' Tax Provisions fell 550.26% to -$27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year increase of 51.25%. This contributed to the annual value of $31.6 million for FY2024, which is 207.03% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Tax Provisions stood at -$27.2 million for Q3 2025, which was down 300.81% from $13.5 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Tax Provisions ranged from a high of $17.3 million in Q4 2024 and a low of -$27.2 million during Q3 2025.
  • Moreover, its 3-year median value for Tax Provisions was $5.2 million (2023), whereas its average is $3.4 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Tax Provisions soared by 2,280.95% in 2022 and then plummeted by 827.32% in 2023.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Tax Provisions stood at $189,000 in 2021, then skyrocketed by 339.68% to $831,000 in 2022, then slumped by 827.32% to -$6.0 million in 2023, then spiked by 386.63% to $17.3 million in 2024, then crashed by 550.26% to -$27.2 million in 2025.
  • Its Tax Provisions was -$27.2 million in Q3 2025, compared to $13.5 million in Q2 2025 and $8.8 million in Q1 2025.